Galenica Group half year results 2021

• By the end of June 2021, more than 80,000 antigen and PCR tests and over 38,000 vaccinations were performed in the pharmacies of the Galenica Group.
• The distribution of COVID-19 self-tests as at 7 April 2021 marked the start of one of the largest distribution campaigns in the history of Swiss pharmacies.
• The importance of pharmacies as the first point of contact for healthcare advice increased even further in the period under review due to COVID-19.
• The logistics companies of the Galenica Group are supporting the authorities to assure COVID-19 vaccination-related logistics.
• Verfora is strengthening its leading position in the Swiss consumer healthcare market through acquisitions and new products.
• Thanks to the doubling of online sales of Amavita and Sun Store and the strong growth of the speciality pharmacy Mediservice, “Pharmacies at Home” (mail-order and Home Care) realised a 30.9% increase in sales.
• New offers for specialised physicians enabled Galexis to gain further market shares.

^{1) Excluding the effects of IAS 19 and IFRS 16. Details of the adjusted key figures are explained in the half year report 2021 of the Galenica Group.}

Due to the strong growth and the good results of the first half year, Galenica revises its sales and EBIT guidance for the 2021 financial year: Provided that the increasing mobility of the population will not be restricted again by tighter official measures, Galenica now expects a sales growth of between 5% and 8% (previously: 3% to 5%) and an increase of the adjusted operating result (EBIT, excluding the effects of IFRS 16 and IAS 19) of between 10% and 14% (previously: 5% to 8%). Ga-lenica thereby expects that colds and seasonal flus will remain at a relatively low level in the coming autumn and winter.